ID
38499
Descripción
Study ID: 110951 Clinical Study ID: 110951 Study Title: A two-part, randomised, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of intravenously infused GSK1995057 in healthy subjects. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01476046 See https://clinicaltrials.gov/ct2/show/NCT01476046 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: N/A, Placebo Trade Name: N/A Study Indication: Respiratory Disorders This phase I trial primarily studies the safety and tolerability of ascending single intravenous doses of the selective TNFR1 antagonist GSK1995057 in healthy volunteers, and secondly explores the drug's pharmacodynamics, pharmacokinetics, concentration in lung epithelial lining fluid as well as its effect on immune system markers. The drug is hypothesized to be useful for Acute Lung Injury. The single-centre study consists of two parts A and B with seven cohorts/ten subcohorts in total. Part A includes ascending doses of the investigational product given to subjects negative or positive for pre-existing human anti-heavy chain variable domain (HAVH) antibodies (Cohorts 1 to 3 with Subcohorts 1a, 2a and 3a negative for HAVH and 1b, 2b, 3b positive for HAVH). Part B includes only subjects negative for HAVH, with ascending doses given to Cohorts 4 to 6. Cohort 7 receives the same dose as Cohort 6, but whereas the other Cohorts are single-blinded, Cohort 7 is open-label and additionally receives a bronchoalveolar lavage (BAL). The study consists of a Screening Visit (up to 56 days before Day 1, the day of the drug administration), Visits on Day -1, 1, 2, 3, 5, 7, 14, 28 and Follow-Up Visits on Day 57 and 85. This form is to be filled in (repeatedly, if necessary) during the study and/or at the end of the study in case of non-serious adverse events.
Link
https://clinicaltrials.gov/ct2/show/NCT01476046
Palabras clave
Versiones (3)
- 22/10/19 22/10/19 -
- 22/10/19 22/10/19 -
- 12/11/19 12/11/19 - Sarah Riepenhausen
Titular de derechos de autor
GlaxoSmithKline
Subido en
22 de octubre de 2019
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY-NC 3.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
Phase I Trial of Intravenous TNFR1 Antagonist GSK1995057 in Healthy Subjects - NCT01476046
Non-serious AE
- StudyEvent: ODM
Descripción
Non-serious adverse event
Alias
- UMLS CUI-1
- C1518404
Descripción
Hidden
Tipo de datos
text
Alias
- UMLS CUI [1,1]
- C2348184
- UMLS CUI [1,2]
- C1518404
Descripción
Diagnosis or Sign/Symptom
Tipo de datos
text
Alias
- UMLS CUI [1]
- C0011900
- UMLS CUI [2]
- C3540840
Descripción
Hidden
Tipo de datos
text
Alias
- UMLS CUI [1]
- C2826798
Descripción
Hidden
Tipo de datos
text
Alias
- UMLS CUI [1]
- C1140263
Descripción
Hidden
Tipo de datos
text
Alias
- UMLS CUI [1]
- C3898442
Descripción
Hidden
Tipo de datos
boolean
Alias
- UMLS CUI [1,1]
- C0805701
- UMLS CUI [1,2]
- C0231175
Descripción
Start Date/Time
Tipo de datos
datetime
Alias
- UMLS CUI [1]
- C2826806
Descripción
if Recovered/Resolved (with or without sequelae) provide End Date and Time
Tipo de datos
integer
Alias
- UMLS CUI [1]
- C1705586
Descripción
if applicable
Tipo de datos
datetime
Alias
- UMLS CUI [1]
- C2826793
Descripción
Non-serious adverse event frequency
Tipo de datos
integer
Alias
- UMLS CUI [1,1]
- C0439603
- UMLS CUI [1,2]
- C1518404
Descripción
[hidden]
Tipo de datos
text
Alias
- UMLS CUI [1]
- C1710066
Descripción
Adverse Event Maximum Grade
Tipo de datos
text
Alias
- UMLS CUI [1,1]
- C0441799
- UMLS CUI [1,2]
- C1710066
Descripción
[hidden]
Tipo de datos
text
Alias
- UMLS CUI [1,1]
- C0441799
- UMLS CUI [1,2]
- C1710066
- UMLS CUI [2,1]
- C0518690
- UMLS CUI [2,2]
- C1518404
Descripción
Action regarding Investigational Product because of non-serious adverse event
Tipo de datos
text
Alias
- UMLS CUI [1,1]
- C1704758
- UMLS CUI [1,2]
- C0566251
- UMLS CUI [1,3]
- C1518404
Descripción
subject withdrawal because of non-serious adverse event
Tipo de datos
text
Alias
- UMLS CUI [1,1]
- C0422727
- UMLS CUI [1,2]
- C0566251
- UMLS CUI [1,3]
- C1518404
Descripción
AE possibly caused by investigational product
Tipo de datos
text
Alias
- UMLS CUI [1,1]
- C0304229
- UMLS CUI [1,2]
- C0085978
- UMLS CUI [1,3]
- C1518404
Descripción
[hidden] If AE start and end time are used this item must be hidden.
Tipo de datos
time
Alias
- UMLS CUI [1,1]
- C0449238
- UMLS CUI [1,2]
- C1518404
Descripción
[hidden]
Tipo de datos
time
Alias
- UMLS CUI [1,1]
- C1272706
- UMLS CUI [1,2]
- C1517741
- UMLS CUI [1,3]
- C0178602
- UMLS CUI [1,4]
- C0439659
- UMLS CUI [1,5]
- C1518404
Similar models
Non-serious AE
- StudyEvent: ODM
C1264639 (UMLS CUI [1,2])
C1518404 (UMLS CUI [1,2])
C3540840 (UMLS CUI [2])
C0231175 (UMLS CUI [1,2])
C1518404 (UMLS CUI [1,2])
C1710066 (UMLS CUI [1,2])
C1710066 (UMLS CUI [1,2])
C0518690 (UMLS CUI [2,1])
C1518404 (UMLS CUI [2,2])
C0566251 (UMLS CUI [1,2])
C1518404 (UMLS CUI [1,3])
C0566251 (UMLS CUI [1,2])
C1518404 (UMLS CUI [1,3])
C0085978 (UMLS CUI [1,2])
C1518404 (UMLS CUI [1,3])
C1518404 (UMLS CUI [1,2])
C1517741 (UMLS CUI [1,2])
C0178602 (UMLS CUI [1,3])
C0439659 (UMLS CUI [1,4])
C1518404 (UMLS CUI [1,5])